Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open label, two centre, randomised controlled trial
Summary Background Because treatment with third generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever. Methods We did an open label, randomised, controlled, superiority trial at two hospitals in the Kathmandu valley, Nepal. Eligible participants were children (aged 2 13 years) and adult (aged 14 45 years) with criteria for suspected enteric fever (body temperature =38*0degC for =4 days without a focus of infection) We randomly assigned eligible patients (1:1) without stratification to 7 days of either oral gatifloxacin (10 mg/kg per day) or intravenous ceftriaxone (60 mg/kg up to 2 g per day for patients aged 2 13 years, or 2 g per day for patients aged =14 years) The randomisation list was computer generated using blocks of four and six. The primary outcome was a composite of treatment failure, defined as the occurrence of at least one of the following: fever clearance time of more than 7 days after treatment initiation; the need for rescue treatment on day 8; microbiological failure (ie, blood cultures positive for Salmonella enterica serotype Typhi, or Paratyphi A, B, or C) on day 8; or relapse or disease related complications within 28 days of treatment initiation. We did the analyses in the modified intention to treat population, and subpopulations with either confirmed blood culture positivity, or blood culture negativity. The trial was powered to detect an increase of 20% in the risk of failure. This trial was registered at ClinicalTrials.gov, number NCT01421693, and is now closed. Findings Between Sept 18, 2011, and July 14, 2014, we screened 725 patients for eligibility. On July 14, 2014, the trial was stopped early by the data safety and monitoring board because S Typhi strains with high level resistance to ciprofloxacin and gatifloxacin had emerged. At this point, 239 were in the modified intention to treat population (120 assigned to gatifloxacin, 119 to ceftriaxone) 18 (15% patients who received gatifloxacin had treatment failure, compared with 19 (16% who received ceftriaxone (hazard ratio [HR] 1*04 [95% CI 0*55 1*98] p=0*91) In the culture confirmed population, 16 (26% of 62 patients who received gatifloxacin failed treatment, compared with four (7% of 54 who received ceftriaxone (HR 0*24 [95% CI 0*08 0*73] p=0*01) Treatment failure was associated with the emergence of S Typhi exhibiting resistance against fluoroquinolones, requiring the trial to be stopped. By contrast, in patients with a negative blood culture, only two (3% of 58 who received gatifloxacin failed treatment versus 15 (23% of 65 who received ceftriaxone (HR 7*50 [95% CI 1*71 32*80] p=0*01) A similar number of non serious adverse events occurred in each treatment group, and no serious events were reported. Interpretation Our results suggest that fluoroquinolones should no longer be used for treatment of enteric fever in Nepal. Additionally, under our study conditions, ceftriaxone was suboptimum in a high proportion of patients with culture negative enteric fever. Since antimicrobials, specifically fluoroquinolones, are one of the only routinely used control measures for enteric fever, the assessment of novel diagnostics, new treatment options, and use of existing vaccines and development of next generation vaccines are now a high priority. Funding Wellcome Trust and Li Ka Shing Foundation.
The Lancet. Infectious diseases